Related by context. All words. (Click for frequent words.) 78 randomized multicenter 77 prospective randomized placebo 76 multicentre randomized 75 double blinded placebo 75 multicenter Phase II 75 double blinded randomized 74 multicenter randomized double 74 multicenter randomized 74 multicenter randomized controlled 74 prospective multicenter 73 prospective multicenter randomized 73 multicenter randomized placebo controlled 73 Phase IIIb 72 multicentre randomized double 72 phase IIIb 72 multicentre 72 nonrandomized 71 multicenter Phase III 71 multicenter phase 71 Phase III randomized 70 placebo controlled randomized 70 Phase III multicenter 70 multicenter prospective 70 active comparator 70 multicenter randomized clinical 70 blinded randomized 70 randomized blinded 70 multicenter clinical 70 multicenter multinational 69 controlled multicenter 69 Randomized Evaluation 69 multicenter placebo controlled 69 placebo controlled Phase III 69 BR.# 69 multicentre prospective 69 Phase III randomized placebo 69 Carotid Revascularization Endarterectomy vs. 69 randomized blinded placebo 69 prospective randomized controlled 69 REALITY Trial 69 BRIM2 69 TMC# C# 69 randomized multicenter trial 69 label multicenter 69 ADVANCE PD 68 randomized multicentre 68 prospective nonrandomized 68 prospective randomized 68 ASTEROID 68 prospective observational 68 blind multicenter 68 CARE HF 68 dose escalation Phase 68 Randomised 68 blind placebo 68 Multicenter 68 randomized controlled multicenter 68 placebo controlled clinical 68 phase IIb clinical 67 Prospective Randomized 67 fosbretabulin 67 multicentre randomized controlled 67 phase IIa 67 Phase III randomized controlled 67 phase IIa clinical 67 ROCKET AF 67 landmark ATHENA 67 RE LY ® 67 randomized Phase III 67 CHAMPION PCI 67 Trandolapril 67 controlled multicenter Phase 67 CIMZIA TM certolizumab pegol 66 AVOREN 66 Phase Ib clinical 66 ECASS 66 randomized controlled Phase 66 #:# randomization 66 randomized Phase IIb 66 phase IIb study 66 NSABP B 66 RE LY 66 prospective multicentre 66 blinded randomized placebo controlled 66 ONTARGET 66 trials RCTs 66 Randomized Double blind 66 Hepatocellular Carcinoma HCC 66 ascending dose study 66 placebo controlled Phase 66 Medidur TM FA 66 EchoCRT 66 tolerability pharmacokinetics 66 Placebo controlled 66 Phase #/#a 66 Phase IIIb study 66 oral rivaroxaban 66 dose dose escalation 66 Randomized controlled 66 Stenting Trial CREST 66 multicenter 65 EURIDIS 65 sequential dose escalation 65 PARTNER Trial 65 Initiated Phase 65 RSD# oral 65 MADIT II 65 randomized crossover 65 Multicenter Randomized Double 65 PFO migraine 65 randomized Phase 2b 65 thorough QT 65 randomized controlled 65 RELOVAIR ™ 65 AIR CF1 65 MEND CABG 65 masked placebo controlled 65 relapsed MM 65 randomized controlled clinical 65 EINSTEIN DVT 65 ZACTIMA 65 pharmacokinetic PK study 65 HCV RESPOND 2 65 AIR CF3 65 Proellex TM 65 IMPACT DCM 65 AIR CF2 65 basal bolus regimen 65 ZYBRESTAT fosbretabulin 65 GOUT 65 Phase IIb III 65 multinational multicenter randomized 65 blind randomized placebo 65 TG MV 65 Safinamide 65 Onrigin 65 blind randomized controlled 65 EmbraceAC 65 Matrix Phase 2b 65 Randomized Clinical Trial 65 NO# [002] 65 treatment naive genotype 65 pain palliation 64 HCV SPRINT 64 ExTRACT TIMI 64 placebo controlled dose escalation 64 placebo controlled studies 64 viral kinetic 64 phase IIb 64 PRECISE 64 PRoFESS 64 ToGA 64 metastatic HRPC 64 retrospective cohort 64 NATRECOR ® 64 Phase 2b randomized 64 Val HeFT 64 Phase III metastatic melanoma 64 Long Lesion 64 relapsed myeloma 64 Telmisartan 64 randomized placebo controlled 64 MIST II 64 candesartan cilexetil 64 blind randomized 64 trastuzumab emtansine T DM1 64 subanalysis 64 LUX Lung 64 CAMMS# 64 Cloretazine 64 Phase Ib II 64 phase Ib 64 multicenter Phase 64 REVIVE Diabetes 64 dose escalation clinical 64 Randomized Phase 64 somatostatin analog 64 label multicenter Phase 64 MAGE A3 ASCI 64 Phase #b/#a clinical 64 PERSEUS 64 placebo controlled 64 RE MODEL 63 randomized 63 Randomized 63 teriflunomide 63 Degarelix 63 Patency 63 placebo controlled multicenter 63 APEX PD 63 GORE TAG Device 63 Alfimeprase 63 Phase 2b kidney transplant 63 Edge STudy 63 everolimus eluting stent 63 Acute Decompensated Heart Failure 63 randomized clinical 63 INSPIRE Trial Phase III 63 AFRS TM 63 BCIRG 63 Vascugel ® 63 AIR2 Trial 63 STRIDE PD 63 Amrubicin 63 unfractionated heparin UFH 63 concurrent chemoradiation 63 YONDELIS 63 galiximab 63 Randomized Phase II 63 randomized placebo 63 registrational Phase 63 EQUIP OB 63 EOquin TM phase 63 prospective multicenter study 63 BRIM3 63 HCV NS5B polymerase 63 RhuDex ® 63 TAXUS IV 63 dose escalation phase 63 Tolvaptan 63 Phase III placebo controlled 63 icatibant 63 Phase IIIb clinical 63 APTIVUS 63 Phase 1b clinical trials 63 riociguat 63 Multiple Ascending Dose 63 Fibrin Pad 63 Phase III confirmatory 63 multicenter randomized Phase III 63 Phase #b/#a 63 EXPLORE Xa 63 PrevOnco 63 label dose titration 63 pharmacokinetic PK 63 brivaracetam 63 reslizumab 63 GEM OS1 63 Deforolimus 63 Thrombolysis 63 Phase III Pivotal 63 TAXUS VI 63 dyskinesia PD LID 63 VADT 63 Teriflunomide 63 RezularTM 63 Dacogen decitabine 63 sirolimus eluting 63 phase III isavuconazole 63 Phase IIB 63 Augment Injectable 63 LUMINATE 63 Zemplar Capsules 63 Daclizumab 63 randomized double 63 blinded placebo controlled 63 Cardiac Allograft Rejection 63 ENDEAVOR IV 63 recurrent glioblastoma multiforme 63 TELCYTA 63 Left Ventricular Dysfunction 63 Mycophenolate Mofetil 63 TAXUS V 63 multicentre study 62 Eculizumab 62 ABSORB trial 62 comparing XIENCE V 62 midstage clinical 62 relapsing multiple sclerosis 62 PROTECT AF 62 Aflibercept 62 DU #b 62 biliary tract cancer 62 abacavir Ziagen 62 Rosuvastatin 62 FIX HF 5 62 Prospective Multicenter 62 TAXUS ATLAS 62 pegylated interferon alfa 2b 62 TRITON TIMI 62 Diabetic Macular Edema DME 62 Controlled Trial 62 multicenter study 62 paclitaxel poliglumex 62 EVEREST II 62 PICSO ® 62 Endovascular Valve Edge 62 DEB# 62 Dabigatran etexilate 62 clevidipine 62 randomized controlled clinical trials 62 mesylate 62 CIMZIA TM 62 prospectively randomized 62 NATRECOR R 62 blind multicentre 62 Temsirolimus 62 investigational protease inhibitor 62 mertansine 62 PEGINTRON TM 62 phase Ib clinical 62 Tocilizumab 62 Acute Ischemic Stroke 62 CALGB 62 pharmacokinetics PK 62 lorcaserin Phase 62 Tanespimycin 62 ongoing Phase 1b 62 CONQUER OB 62 Apixaban 62 phase IIb trial 62 Prospective Randomized Trial 62 YONDELIS R 62 dosing cohorts 62 sorafenib Nexavar 62 EDEMA3 62 PREZISTA r 62 unique alkylating agent 62 SPIRIT FIRST 62 GW# [003] 62 ascending dose 62 AVERROES 62 PROMUS R 62 pharmacodynamic profile 62 CANCIDAS 62 Phase 2b study 62 LHRH receptor positive 62 label multicenter randomized 62 Bayer HealthCare Onyx Pharmaceuticals 62 trial evaluating PRX# 62 evaluating tivozanib 62 PROMUS Element Stent 62 zotarolimus 62 Phase III VISTA 62 randomized #:#:# 62 everolimus eluting stents 62 IL# PE#QQR 62 colesevelam HCl 62 budesonide foam 62 Betaferon ® 62 Phase IIb randomized 62 Sorafenib HCC Assessment 62 PROSTVAC ® 62 MIVI III 62 Alocrest 62 patientswith 62 liposomal formulation 62 Phase 1b clinical 62 recurrent malignant glioma 62 Sapacitabine 62 AIM HIGH 62 comparator arm 62 KRN# 62 rALLy clinical trial 62 neratinib 62 CLARITY TIMI 62 retinal vein occlusion induced 62 BARI 2D 62 PD LID 62 Ozarelix 62 non inferiority 62 RECORD1 62 factorial design 62 Non inferiority 62 AKT inhibitor 62 GEM OS2 62 noninferiority 62 pivotal bioequivalence 61 Lodotra TM 61 Tarceva TM 61 MGd 61 XIENCE V Everolimus Eluting 61 Infarct 61 TLK# 61 dabigatran etexilate 61 CLL8 61 NICE SUGAR 61 LAB CGRP 61 CIMZIA ™ 61 nab paclitaxel 61 Afatinib 61 interferon beta 1b 61 PRECiSE 61 efficacy endpoint 61 NP2 Enkephalin 61 Pertuzumab 61 Naive Patients 61 MVA MUC1 IL2 61 Ranolazine 61 relapsing remitting MS RRMS 61 CALGB # [002] 61 BoNTA 61 Dapagliflozin 61 stage IIIB 61 pharmacodynamic effects 61 PI3K/Akt pathway inhibitor 61 ATACAND 61 pegylated liposomal doxorubicin 61 PRE SURGE 61 phase 2a 61 Intervention Effectiveness 61 Placebo Controlled 61 Ranibizumab 61 vinca alkaloid 61 irbesartan 61 docetaxel Taxotere ® 61 sorafenib tablets 61 number NCT# ClinicalTrials.gov 61 Epirubicin 61 RRMS patients 61 ACTEMRA TM 61 ritonavir boosted 61 substudy 61 Liraglutide Effect 61 ancrod 61 #mg QD [002] 61 TASKi2 61 PRIMO CABG 61 5 fluorouracil leucovorin 61 LEXIVA r 61 IV NSCLC 61 prucalopride 61 XIENCE TM 61 vapreotide acetate 61 pertuzumab 61 FOLOTYN ® 61 cediranib 61 EOquin TM 61 pegnivacogin 61 oral ridaforolimus 61 STENT 61 dose escalation trial 61 gadobutrol 61 rFVIIa 61 receptor tyrosine kinase inhibitor 61 Proxinium TM 61 eluting stent 61 Phase Ib study 61 Critical Limb Ischemia CLI 61 ATTRACT 61 evaluating REVLIMID 61 sunitinib malate 61 By JENNIFER LEARN 61 6R BH4 61 designated HVTN 61 oral Janus kinase 61 GSK# [001] 61 Xelox 61 ENGAGE AF TIMI 61 cisplatin gemcitabine 61 Pemetrexed 61 Fx #A 61 FDA Investigational Device 61 Trial ASCOT 61 tanespimycin 61 ADMIRE HF 61 ug dose 61 beta 1a 61 multicenter randomized Phase 61 Pivotal Trial 61 afamelanotide 61 double blind placebo 61 Eluting Stent 61 Double Blind Placebo 61 Edoxaban 61 recurrent metastatic 61 cetrorelix pamoate 61 chronic thromboembolic pulmonary 61 retrospective observational study 61 Aplidin R 61 initiate multicenter 61 bioequivalency 61 NCT# ClinicalTrials.gov 61 Sirolimus eluting Coronary Stent 61 GATTEX ® 61 Randomized Study 61 HORIZONS AMI 61 Microplasmin 61 Kahalalide F 61 Zyclara 61 Subgroup analysis 61 CATIE AD 61 miconazole Lauriad ® 61 denileukin diftitox 61 Phase Ia 61 postmenopausal osteoporotic women 61 eprotirome 61 buccal spray 61 Eluting Coronary Stent System 61 liposome injection 61 Qutenza TM 61 Deferiprone 61 RAVEL 61 Glatiramer Acetate 61 treatment naïve genotype 61 factor Xa inhibitor 61 GATTEX ™ 61 lexidronam injection 61 ACCOMPLISH 61 somatostatin analogue 61 REVLIMID lenalidomide 61 ALN VSP Phase 60 PSMA ADC 60 liposomal doxorubicin 60 patients undergoing percutaneous 60 docetaxel Taxotere R 60 Phase 2a clinical 60 Sipuleucel T 60 OvaRex ® MAb 60 Darusentan 60 confirmatory clinical 60 JAK inhibitor 60 Phase Ib 60 Navelbine ® 60 Candesartan 60 tramiprosate Alzhemed TM 60 CYT# potent vascular disrupting 60 randomized dose escalation 60 Pre RELAX AHF 60 multicentric 60 TM Drug Eluting 60 pregabalin Lyrica 60 NEVO 60 regorafenib 60 Initiate Phase 60 Prostate Lung Colorectal 60 randomized discontinuation 60 papillary renal cell carcinoma 60 CYPHER Stent 60 TASKi3 60 Xanafide 60 prospectively defined 60 Methylnaltrexone 60 acetonide FA 60 Phase IIA 60 NCIC CTG 60 Randomized Double Blind Placebo 60 Study Evaluating 60 efavirenz EFV 60 Multicenter Randomized 60 fostamatinib 60 either acutely decompensated 60 SPIRIT IV 60 Dabigatran 60 PROTEGE 60 virus HCV protease inhibitor 60 observational cohort 60 Meets Primary Endpoint 60 MEND CABG II 60 SinuNase TM 60 intravesical infusion therapy 60 DEEP AF 60 RE LY trial 60 Olmesartan 60 Rilonacept 60 histologically confirmed 60 idraparinux 60 salmeterol fluticasone 60 Betaferon R 60 Polyp Prevention Trial 60 glycoprotein IIb IIIa inhibitor 60 MKC# MKC# PP 60 Phase III ADT 60 metastatic malignant 60 Multicenter Automatic Defibrillator Implantation 60 ischemic cardiomyopathy 60 Velcade bortezomib 60 Adalimumab 60 HuMax EGFr 60 Clinical Antipsychotic Trials 60 intravenous RSD# 60 Myocet 60 PHX# 60 BRAF inhibitor 60 Phase IIb clinical trials 60 PSN# [002] 60 oral antiplatelet agent 60 morphometric vertebral fractures 60 ALLEGRO 60 Pivotal Clinical Trial 60 GAMMAGARD 60 Parkinson disease levodopa induced 60 preclinical efficacy 60 brivanib 60 Phase Ib IIa 60 platelet inhibitor 60 ZOLINZA 60 Current Controlled Trials 60 INTEGRILIN R 60 pharmacodynamic profiles 60 melphalan prednisone 60 RIO Lipids 60 CALERIE 60 NOX E# 60 direct thrombin inhibitors 60 Elvitegravir 60 tolevamer 60 Enzastaurin 60 vinorelbine tartrate 60 UPLYSO 60 GSK# [002] 60 TBC# 60 Sym# 60 Pirfenidone 60 VICTOR E1 60 darunavir ritonavir 60 label dose escalation 60 Androxal TM 60 long acting bronchodilator 60 REG1 60 Metabolic Efficiency 60 liver resection 60 novel VDA molecule 60 mg administered orally 60 Severe Sepsis 60 subgroup analyzes 60 Phase III psoriasis 60 Myocardial Infarction Study 60 oral dual endothelin 60 NAVISTAR R 60 TRANSFORMS 60 Non Alcoholic Steatohepatitis 60 VITAL Trial 60 fistulizing Crohn disease 60 Nebulized 60 Phase IIa trial 60 MEVACOR 60 undergoing elective percutaneous 60 myoblast therapy 60 Aneurysm Repair 60 subcutaneous SC 60 Randomized Controlled 60 Ceplene/IL-2 60 nucleoside analog 60 ACTIVE W 60 Dacogen injection 60 Sibutramine Cardiovascular Outcomes 60 StemEx R 60 DAPT Study 60 posaconazole 60 observational cohort study 60 severe gastroparesis 60 rosuvastatin Crestor 60 cinacalcet 60 Sirolimus eluting 60 EXPAREL TM 60 CCR5 mAb 60 percutaneous vertebroplasty 60 CRLX# 60 Pooled Analysis 60 OMS# 60 dasatinib Sprycel ® 60 UKPDS 60 gefitinib Iressa 60 placebo controlled trials 60 REFLEX 60 ER CHOP 60 thalidomide Thalomid 60 ThermoDox R 60 safety tolerability pharmacokinetic 60 Raloxifene Evaluation MORE 60 intravitreal insert 60 keloid scarring 60 bevirimat Study 60 standard chemotherapy regimen 60 erlotinib Tarceva ® 60 ILLUSTRATE 60 ABSORB clinical 60 Prostate AdenoCarcinoma Treatment 60 dirucotide MBP# 60 echinocandin 60 olmesartan 60 non valvular atrial 60 SORT OUT 60 bevacizumab Avastin R 60 multicenter trials 60 MERLIN TIMI 60 bevacizumab Avastin ® 60 hemostatic efficacy 60 Androgel R 60 DAPT 60 Nesiritide 60 Diabetic Macular Edema 60 RhuDex 60 tasocitinib 60 Mg Usa 60 Platelet Inhibition 60 opioid induced bowel dysfunction 60 Phase #b/#a trial 60 Adenoma Prevention 59 REVIVE TA 59 Valsartan 59 VICTOR E3 59 Denufosol 59 CLARITY study 59 ZoMaxx 59 OLYMPIA registry 59 MIVI TRUST 59 Vascugel 59 Pharmacokinetic PK 59 BAY #-# 59 acadesine 59 BrachySil 59 Cannabinor 59 EGS# 59 Intravitreal 59 beta2 agonist 59 Glypromate 59 cromolyn sodium 59 OZURDEX ® 59 crizotinib PF # 59 Phase IIa clinical 59 RhuDex TM 59 SCH # 59 acyclovir Lauriad R 59 cathepsin K inhibitor 59 Intervention Trial GAIT 59 phase IIb III 59 Zometa zoledronic acid 59 WHIMS 59 Stage IIIb 59 radiolabeled TM# 59 Tyrima 59 CYT# QbG# 59 NeuroSTAT ® 59 diarrhea predominant irritable 59 Primary endpoints 59 ORMD 59 Remission Maintenance 59 DIRECT Trial 59 cortical stimulation 59 weekly subcutaneous injections 59 Zybrestat 59 Randomized Double Blind 59 Neovascular AMD 59 RE SURGE 59 abacavir lamivudine 59 metastatic androgen independent 59 Phase 2b clinical trials 59 Phase 2a trial 59 unblinded 59 Stent Restenosis 59 oral deforolimus 59 OPT CHF 59 HPTN 59 Dr. Kandzari 59 EXPAREL ™ 59 GORE VIABAHN Endoprosthesis 59 #mg BID [001] 59 inhaled AAT 59 MabCampath 59 Traficet EN 59 nonsmall cell lung cancer 59 FAME Study 59 Glycopyrrolate 59 inhibitor RG# 59 azilsartan medoxomil 59 Aggressive Reduction 59 cetuximab Erbitux R 59 iloprost 59 Vascular Wrap 59 histone deacetylase inhibitor 59 DDP# 59 Decitabine 59 stage IIIb IV 59 clazosentan 59 bovine thrombin 59 pan HDAC inhibitor 59 CEQ# 59 dose titration 59 efficacy tolerability 59 induced macular edema 59 Phase Ib clinical trials 59 canakinumab 59 tacrolimus ointment 59 elotuzumab 59 trabectedin 59 carotid artery stenting CAS 59 targeting miR 59 Anti Bacterial Envelope 59 cilengitide 59 Solesta 59 noninferior 59 Recurrent Glioblastoma 59 EGFR HER2 59 multidose 59 tolvaptan 59 unstable angina UA 59 RG# ITMN 59 transurethral 59 Pegylated Liposomal Doxorubicin 59 mapatumumab 59 Liprotamase 59 ACCEDE 59 COSIRA trial 59 FOLFOX4 59 PEG IFN 59 transcranial Doppler ultrasound 59 MIRCERA 59 Randomized Placebo Controlled 59 Tracleer R 59 CURE AF 59 ACTOS ® 59 DUROS 59 herpetic keratitis 59 risperidone Risperdal 59 dexpramipexole 59 thetreatment 59 ADAGIO study 59 Tiotropium 59 Anturol TM 59 MADIT 59 TEMSO 59 Fondaparinux 59 nilotinib Tasigna ® 59 rosuvastatin #mg 59 Phase 1b trial 59 rituximab Rituxan 59 mixed hyperlipidemia 59 MKC# MT 59 sorafenib Nexavar ® 59 ASCEND HF 59 administered subcutaneously 59 kidney urologic 59 ritonavir boosted lopinavir 59 Yondelis ® 59 BENICAR HCT 59 migraine prophylaxis 59 Coronary Artery Bypass Graft 59 mg/m2 dose 59 BETAS 59 telaprevir dosing 59 Nexavar sorafenib 59 fluticasone furoate 59 Pivotal Phase 59 liver transplant recipients 59 randomized #:# 59 complement inhibitor eculizumab 59 anticancer compound 59 sitaxsentan 59 trastuzumab DM1 T DM1 59 ZYBRESTAT TM 59 DermaVir Patch 59 confirmatory Phase 59 Triapine 59 nadroparin 59 pharmacodynamic properties 59 mITT population 59 BARACLUDE ® 59 longitudinal cohort study 59 Oral Fingolimod 59 Asthma Intervention 59 Meta analyzes 59 Mipomersen 59 REGEN trial 59 desvenlafaxine succinate 59 paclitaxel eluting 59 EndoTAG TM -1 59 genotypic resistance 59 reteplase 59 GELA 59 Phase IIb clinical 59 Tumor Response 59 biologic DMARD 59 aripiprazole Abilify 59 Double Blind Randomized 59 Ixempra 59 Cypher Sirolimus 59 genotype 1a 59 PKC# 59 Secondary efficacy endpoints 59 anti arrhythmic drug 59 PDX pralatrexate 59 sirolimus eluting stent 59 Zevalin consolidation 59 Neovascular Age Related Macular 59 Refractory Angina 59 milrinone 59 trastuzumab Herceptin R 59 Glufosfamide 59 TM Everolimus Eluting 59 uremic pruritus 59 Clolar ® 59 etanercept Enbrel 59 ASPIRE HIGHER 59 symptomatic paroxysmal AF 59 Intervention Effectiveness CATIE 59 superficial bladder cancer 59 Interagency Registry 59 Multicenter Phase 59 atrasentan 59 Complications Trial 59 SORT OUT III 59 Dose Ranging Study 59 Pyridorin 59 Diabetic Foot Ulcer 59 constipation OIC 59 Ziprasidone 59 Mg Uk 59 GRNVAC1 59 Oral Insulin 59 PEARL SC 59 evaluating Vectibix 59 SPL# Gel vaginal microbicide 59 RhuDex R 59 fenofibric acid 59 bortezomib Velcade R 59 HQK 59 doripenem 59 rt PA 59 cilostazol 59 aflibercept VEGF Trap 59 Teplizumab 59 fallopian tube cancers 59 carisbamate 59 cannabinor 59 pharmacokinetics pharmacodynamics 59 BrachySil ™ 59 Enzyme Replacement Therapy 59 LymphoStat B belimumab 59 serotonin norepinephrine reuptake inhibitor 59 aspirin clopidogrel 59 retrospective cohort study 59 ORAL Sync 59 Abciximab 59 Moxifloxacin 59 Phase III Clinical Trial 59 PROactive study 59 ILUVIEN ® 59 Golimumab 59 Phase III ThermoDox 59 bevacizumab Avastin 59 vidofludimus 59 interferon gamma 1b 59 peritumoral brain edema 59 Acute Myocardial Infarction 59 dosing cohort 59 metastatic hormone refractory 59 capecitabine Xeloda R 59 VNP#M 59 Elagolix 59 recombinant tissue plasminogen 59 tigecycline 59 hypoxia activated prodrug 59 AFREZZA TM 59 orally inhaled migraine 59 chemoradiation therapy 59 Folfox 59 Cloretazine ® 59 HepaMate 59 intravenously administered 59 CR# vcMMAE 59 ANCHOR trial 59 IMPROVE HF 59 randomized multicenter Phase III 59 TNF alpha inhibitor 59 Silodosin 59 liver resection surgeries 59 Panzem NCD 59 Protelos 59 BLP# Liposome Vaccine 59 Pafuramidine 59 mg q#h 59 Scandinavian Simvastatin Survival 59 transesophageal echocardiography 59 COPERNICUS 59 durable pain palliation 59 Myelodysplastic Syndrome MDS 58 subcutaneous PRO 58 Carfilzomib 58 Phase IIa trials 58 everolimus eluting 58 CAELYX 58 Prosaptide 58 ALGRX 58 PCI ExTRACT TIMI 58 EMPHASIS HF trial 58 SUTENT ® 58 CBLC# 58 evaluating Actimmune 58 longitudinal observational study 58 computed tomographic 58 Resten NG 58 AEGR 58 methylnaltrexone bromide 58 QD dosing 58 R# #mg BID 58 CRVO 58 Long Term Efficacy 58 PROSTVAC TM 58 Squalamine 58 undergone radical prostatectomy 58 STARFlex 58 ALVESCO R 58 fluvastatin 58 ALN HPN 58 topically administered 58 BZA CE 58 SinuNase ™